Nanobiotix stock analysis
Want to see FR:NANO full AI Analyst Report?
Nanobiotix (NANO) Stock Price & Analysis
NANO Stock Chart & Stats
- Day’s Range
- EUR 27.28 - EUR 29.00
- 52-Week Range
- EUR 16.52 - EUR 47.66
- Previous Close
- EUR 29.04
- Volume
- N/A
- Average Volume (3M)
- 211.17K
- Market Cap
- EUR 1.42B
- Enterprise Value
- EUR 1.56B
- Total Cash (Recent Filing)
- EUR 110.89M
- Total Debt (Recent Filing)
- EUR 106.61M
- Price to Earnings (P/E)
- ―
- Beta
- 0.52
- Next Earnings
- Apr 27, 2027 (Est.)
- EPS Estimate
- 0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Nanoparticle Oncology Platform
The NBTXR3 platform gives Nanobiotix a differentiated technology focus within oncology, where improving the effectiveness of established radiotherapy could support multiple solid-tumor applications. If clinical development succeeds, the platform approach may create broader growth potential than a single-indication therapy.
2025 Revenue Growth
The sharp 2025 revenue increase indicates that the company has demonstrated some ability to generate commercial or partnership-related top-line activity after an inconsistent prior period. Continued conversion of development progress into revenue could improve operating leverage and support longer-term funding capacity.
High Gross Margin
A 100% gross margin suggests that reported 2025 revenue carried substantial contribution before operating expenses, leaving theoretical room for future profitability if revenue becomes more stable and scales. This is a potentially favorable economic feature, although it has not yet offset the company’s development spending.
Bears Say
Persistent Losses
Persistent operating and net losses show that Nanobiotix has not yet established repeatable earnings power. Continued deficits can constrain strategic flexibility and require additional financing, while the absence of demonstrated profitability makes future results highly dependent on successful clinical and commercial execution.
Ongoing Cash Burn
Consistently negative operating and free cash flow means reported activity is not currently funding the business internally. Although 2025 cash burn was lower than the prior year, the company still consumes cash, which can force reliance on external capital and limit its ability to sustain development independently.
Negative Equity And Rising Debt
Negative shareholders’ equity materially weakens the balance sheet and reduces financial flexibility, while higher debt increases the burden on a company that is already loss-making and cash-burning. This capital structure can make future funding more difficult and heightens sensitivity to financing requirements.
Nanobiotix News
NANO FAQ
What was Nanobiotix’s price range in the past 12 months?
What is Nanobiotix’s market cap?
When is Nanobiotix’s upcoming earnings report date?
How were Nanobiotix’s earnings last quarter?
Is Nanobiotix overvalued?
Does Nanobiotix pay dividends?
What is Nanobiotix’s EPS estimate?
How many shares outstanding does Nanobiotix have?
What happened to Nanobiotix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nanobiotix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Laurent Levy
- Employees
- 98
- Website
- www.nanobiotix.com
- Address
- 60 rue de Wattignies, Paris, IF, 75012, FR
Nanobiotix (NANO) Earnings & Revenues
NANO Earnings Call
Earnings Call SentimentPositive
The call presented several concrete operational and financial improvements: a strengthened balance sheet via nondilutive financing, a meaningful reduction in R&D expense tied to the Janssen transfer, a much smaller net loss, progressing late-stage trials run by J&J (Phase III head & neck and randomized Phase II lung) and clear advancement of the Curadigm platform (patents, MTAs, GMP/CMC steps). However, many positives are tempered by important caveats: the 2025 revenue improvement is substantially a one-time accounting adjustment, early clinical data (CONVERGE safety lead-in) are from a very small cohort, key development and commercialization decisions rest with J&J, and the cash runway depends on future contingent payments. Overall, operational momentum and improved financial flexibility weigh strongly in favor of a positive view, but execution and J&J-dependent milestones remain critical risks.
View all FR:NANO earnings summariesNANO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 6 | 0 | 6 |












